8WRD image
Entry Detail
PDB ID:
8WRD
EMDB ID:
Title:
Human VMAT2 in the apo state
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-10-13
Release Date:
2024-09-25
Method Details:
Experimental Method:
Resolution:
3.05 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Synaptic vesicular amine transporter
Chain IDs:A
Chain Length:514
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:FabH
Chain IDs:C (auth: H)
Chain Length:336
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Description:FabL
Chain IDs:B (auth: L)
Chain Length:220
Number of Molecules:1
Biological Source:Mus musculus
Ligand Molecules
Primary Citation
Neurotransmitter recognition by human vesicular monoamine transporter 2.
Nat Commun 15 7661 7661 (2024)
PMID: 39284862 DOI: 10.1038/s41467-024-51960-z

Abstact

Human vesicular monoamine transporter 2 (VMAT2), a member of the SLC18 family, plays a crucial role in regulating neurotransmitters in the brain by facilitating their uptake and storage within vesicles, preparing them for exocytotic release. Because of its central role in neurotransmitter signalling and neuroprotection, VMAT2 is a target for neurodegenerative diseases and movement disorders, with its inhibitor being used as therapeutics. Despite the importance of VMAT2 in pharmacophysiology, the molecular basis of VMAT2-mediated neurotransmitter transport and its inhibition remains unclear. Here we show the cryo-electron microscopy structure of VMAT2 in the substrate-free state, in complex with the neurotransmitter dopamine, and in complex with the inhibitor tetrabenazine. In addition to these structural determinations, monoamine uptake assays, mutational studies, and pKa value predictions were performed to characterize the dynamic changes in VMAT2 structure. These results provide a structural basis for understanding VMAT2-mediated vesicular transport of neurotransmitters and a platform for modulation of current inhibitor design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures